A white powder arrives in a glass vial with a rubber stopper, a crimped aluminium seal and no dose a pharmacist would recognise. Inside the hour, somebody with no experience preparing a sterile injectable will dissolve it in water at a kitchen table and put it under their skin, and a 12-minute video will have told them they are being careful.
This page will not help them do it.
Direct answer: for the peptides sold as research chemicals there is no safe home answer to how to reconstitute peptides, because the substance has not been approved, the vial carries no reviewed labelling, and the federal record describes what happens when people measure these products themselves.
Take a side, since the videos will not. The tutorial is the most dangerous document in this market. It hands a stranger the confidence of a pharmacist and none of the pharmacy.
How to Reconstitute Peptides – The Question Hides a Missing Label
Reconstitution is not complicated as chemistry. A lyophilised, freeze-dried powder gets dissolved in a diluent so it can be drawn into a syringe. Every approved injectable that ships as a powder carries a document saying which diluent, which volume, which storage temperature and which discard date, and that document was read by regulators before anyone sold it.
DailyMed holds those documents. Tesamorelin, sold as Egrifta and distributed as a kit, has a label published there on 3 August 2026. Bremelanotide, sold as Vyleesi, has one published 18 November 2025. Those are the paper trail of an approved product.
A vial bought from a research-chemical shop has no equivalent page, because there is no approved product behind it. One of these is a document a government can hold a company to. The other is a shopping cart with a comment section.
BPC-157 – FDA Wrote Down What It Does Not Know
FDA’s page on bulk drug substances that may present significant safety risks carries two tables worth reading before the powder dissolves. The page content is current as of 22 April 2026.
The second table lists substances that were nominated for compounding and then withdrawn. It has 17 rows, and they read like the menu of a peptide shop: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide, epitalon, GHK-Cu, ipamorelin acetate, KPV, PEG-MGF, Melanotan II, MOTs-C, selank acetate, semax, thymosin beta-4 fragment and thymosin-alpha 1.
BPC-157’s own row says compounded drugs containing it may pose a risk of immunogenicity, that FDA has identified no, or only limited, safety-related information for the routes people use, and that the agency therefore lacks sufficient information to know whether the drug would cause harm when administered to humans.
The same page keeps a category 2 table for substances where FDA did identify significant risks, with the date each was added. Growth hormone releasing peptide-2 and peptide-6, ibutamoren mesylate and ipamorelin acetate joined that list on 29 September 2023. Fourteen substances sit in it.
The withdrawal was the nominator’s choice. The safety finding stayed on the agency’s website.
How to Reconstitute Peptides in a Pharmacy – 503A Sets the Bar
Federal law already describes the version of this procedure that is allowed, and it is not performed at a table. On FDA’s page for bulk drug substances used in compounding under section 503A, a state-licensed physician or pharmacist may compound only with ingredients that meet one of three tests: they comply with an applicable United States Pharmacopeia or National Formulary monograph and the USP chapter on pharmacy compounding; or they are components of FDA-approved drug products; or they appear on FDA’s 503A bulks list.
The ingredient must also arrive with a valid certificate of analysis and must come from an establishment registered with FDA. The agency’s guidance to compounders on this point is blunt: know your bulk supplier.
The list itself moves slowly and by rulemaking. A final regulation in February 2019 placed six substances on the 503A list and declined to place four others. A proposed regulation in September 2019 proposed adding five and not adding 26. Under the interim policy that governs the gap, category 1 substances fall outside enforcement discretion, while category 2 substances do not, because the agency has already identified significant safety risks for them.
A pharmacy reconstitutes under a rule that names the powder, the supplier and the paperwork. A kitchen counter reconstitutes under a video. The certificate of analysis is the part no camera records.
The 28-Day Rule – The Vial Outlives Its Own Instructions
FDA’s page on unapproved GLP-1 drugs used for weight loss sets out what a multi-dose vial of a sterile medication is supposed to be: used within 28 days after the first use, then discarded, even if medication remains in it. FDA recommends discarding it inside that window even when the compounder’s own instructions say it can be used longer. A new sterile needle and syringe for each dose, because reusing them can contaminate the vial.
Read that twice. The federal recommendation and the seller’s instruction sheet are allowed to disagree, and the seller wins the argument in most kitchens.
The same page carries the count. As of 31 May 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. State-licensed pharmacies that are not outsourcing facilities are not required to report, so the real numbers sit higher.
FDA also describes the failure it hears about most: multiple reports of adverse events, some requiring hospitalisation, tied to dosing errors with compounded injectable semaglutide, caused by patients measuring and self-administering incorrect doses. In some cases health care professionals miscalculated too.
The error is measured in millilitres. The bill arrives in an emergency department.
Melanotan II – The Case Reports That Fit on One Line
Some of the safety summaries on that FDA page do not need interpreting. The entry for Melanotan II records published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. CJC-1295 carries serious adverse events including increased heart rate and a systemic vasodilatory reaction. GHK-Cu, for injectable routes, is described as having limited human data.
These are not the claims of a competitor or a news outlet. This is the agency’s summary of what it found when it looked.
The Label That Says Research Only – FDA Read It as Human Use
Products in this market often arrive with a phrase on the packaging that is doing legal work: for research purposes, or not for human consumption. FDA has a position on that sentence. The agency warns of companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide, falsely labelled for research purposes or not for human consumption, and it notes what happened next: the products were sold directly to consumers for human use with dosing instructions.
The same page lists the warning signs FDA tells consumers to look for, and most of them are structural rather than criminal. A seller that does not require screening and a prescription from a licensed doctor before sending medicine. A seller with no licensed doctor available to answer questions afterwards. Claims that a compounded drug is the same thing as an approved one. Labels with spelling errors or a pharmacy address that does not check out. Fraudulent compounded products found with the name of a real licensed pharmacy that did not make them.
Two more of FDA’s findings remove any doubt about the chemistry being incidental. Semaglutide sodium and semaglutide acetate, salt forms found in some compounded products, are different active ingredients from the one in the approved drug, and the agency says it is not aware of any lawful basis for using them in compounding. And compounded injectables have arrived warm, or with inadequate ice packs, after shipping. FDA’s advice on that is to not use them.
Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of any approved drug and carry no finding of safety or effectiveness for any condition.
An Honest Answer Looks Like a Prescription
FDA’s own recommendations for this situation are short, and they are not a mixing procedure. Use a compounded drug only where an approved drug cannot meet the medical need. Get a prescription from a doctor and fill it at a state-licensed pharmacy. Check the pharmacy through the agency’s BeSafeRx campaign before sending money to a website.
None of that is as fast as a video. It is, however, the only version of this where somebody is accountable when the dose is wrong.
Patients comparing options in a city can start by looking at licensed clinics rather than at research-chemical shops. Two of our earlier pages sit directly beside this one and are worth reading next: why a peptide calculator is not a dose and which peptides FDA has flagged and why.
Frequently asked questions
Can I reconstitute peptides at home safely?
No. FDA’s safety page identifies no, or only limited, safety-related information for the routes these substances are put to, and states that the agency lacks sufficient information to know whether they would cause harm in humans. A procedure cannot be made safe by technique when the substance and the dose are both uncharacterised.
How much bacteriostatic water should I add to a peptide vial?
There is no official amount, because there is no approved product, no reviewed label and no pharmacopoeial monograph for these substances in this use. Any figure on a seller’s page or in a YouTube description is that seller’s own number, not a regulatory one. We do not reproduce those figures, and dosing advice is not something a directory can give.
Is a reconstituted peptide vial sterile?
Not by default. Sterility comes from the way a product is manufactured and handled, not from the powder itself. FDA recommends a new sterile needle and syringe for each dose and says a vial containing multiple doses of a sterile medication should be used within 28 days of first use, then discarded, because contamination risk rises after that.
How long does a reconstituted peptide vial last?
FDA’s guidance for multi-dose sterile vials is 28 days from the first use, and it recommends discarding the vial inside that window even if medication remains, and even where the compounder’s instructions say otherwise. Anything longer is a seller’s claim, not an agency recommendation.
Why does my peptide vial say for research use only?
FDA has warned companies that sold unapproved drugs falsely labelled for research purposes or not for human consumption while selling them directly to consumers for human use, complete with dosing instructions. The wording on the vial and the way the product is sold can point in opposite directions, and the agency treats the sale, not the sticker, as the conduct.
Is compounded semaglutide the same as Ozempic?
No. Compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed. FDA has also found salt forms such as semaglutide sodium and semaglutide acetate in compounded products, and those are different active ingredients from the one in the approved drug.
Where can I get peptides legally?
Through a prescription from a licensed clinician, filled at a state-licensed pharmacy, and only where an approved drug cannot meet the medical need, in FDA’s own words. Retatrutide and cagrilintide cannot be used in compounding under federal law at all. A directory of licensed clinics is a better starting point than a research-chemical shop.
Sources: FDA, FDA, FDA, DailyMed. Retrieved 16 October 2026.
The site question has a companion, and the labels settle it before the blog posts do: where the approved peptide labels allow an injection, and which zones they rule out.